Table 4.

Characteristics and outcomes of SRG patients in the ALL-Moscow–Berlin 2002 trial by randomization arm

	Disease-free survival (DFS)		р	Overall survival (OS)		р
	Arm ASP-5000	Arm ASP-10000		Arm ASP-5000	Arm ASP-10000
Gender
Boys	80 ± 3%	72 ± 3%	0.03	84 ± 4%	81 ± 3%	0.05
Girls	78 ± 3%	80 ± 3%	0.81	84 ± 3%	83 ± 3%	0.83
Age (years)
≥ 1–< 5	84 ± 3%	79 ± 3%	0.20	88 ± 4%	83 ± 3%	0.04
≥ 5–< 10	78 ± 4%	76 ± 4%	0.72	83 ± 4%	85 ± 4%	0.70
≥ 10	70 ± 5%	63 ± 6%	0.27	80 ± 5%	74 ± 5%	0.23
Initial white blood cell count
< 10,000/µl	80 ± 3%	76 ± 3%	0.25	85 ± 3%	83 ± 3%	0.23
≥ 10,000–< 30,000/µl	78 ± 4%	77 ± 4%	0.82	81 ± 6%	84 ± 4%	0.78
≥ 30,000–< 50,000/µl	77 ± 9%	64 ± 8%	0.28	86 ± 7%	70 ± 8%	0.16
Genetics
t(12;21)	93 ± 5%	88 ± 7%	0.51	83 ± 13%	100 ± 0%	0.24
Induction therapy
Dexamethasone 6 mg/m2	80 ± 3%	78 ± 3%	0.49	84 ± 3%	83 ± 3%	0.42
Methylprednisolone 60 mg/m2	79 ± 3%	72 ± 3%	0.17	85 ± 4%	80 ± 3%	0.12

DFS was significantly superior in boys, and OS higher in boys and young children (aged ≥ 1–< 5 years) in the arm ASP-5000 than in the arm ASP-10000. DFS was independent of other patient characteristics shown, in particular of the glucocorticoid used during induction (Dexamethasone vs. Methylprednisolone)

Statistical significant р values are in bold